Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone (original) (raw)
References
Bellido T, Afshan Ali A, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O’Brien CA, Manolagas SC, Jilka RL (2003) Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. J Biol Chem 278:50259–50272 ArticlePubMedCAS Google Scholar
Bellido T , Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, Manolagas SC, Jilka RL (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577–4583 ArticlePubMedCAS Google Scholar
Bianco P, Ballanti P, Bonucci E (1988) Tartrate-resistant acid phosphatase activity in rat osteoblasts and osteocytes. Calcif Tissue Int 43:167–71 ArticlePubMedCAS Google Scholar
Fermor BST (1995) PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. J Bone Min Res 10:1935–1943 CAS Google Scholar
Gardner JC, van Bezooijen RL, Mervis B, Hamdy NAT, Löwik CWGM, Hamersma H, Beighton P, Papapoulos SE (2005) Bone mineral density in sclerostosis; affected individuals and gene carriers. J Clin Endocrinol Metab 90:6392–6395 ArticlePubMedCAS Google Scholar
Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2–12 ArticlePubMedCAS Google Scholar
Isogai Y, Akatsu T, Ishizuya T,Yamaguchi A, Hori M,Takahashi N, Suda T (1996) Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages. J Bone Min Res 11:1384–1393 ArticleCAS Google Scholar
Jackson A, Vayssiere B, Garcia T, Newell W, Baron R, Roman-Roman S, (2005) Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 36:585–598 ArticlePubMedCAS Google Scholar
Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass II DA, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L (2002) _Cbfa1_-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157:303–314 ArticlePubMedCAS Google Scholar
Kolpakova E, Olsen BR (2005) Wnt/beta-catenin–a canonical tale of cell-fate choice in the vertebrate skeleton. Dev Cell 8:626–627 ArticlePubMedCAS Google Scholar
Langub MC, Monier-Faugere MC, Qi Q,Geng Z, Koszewski NJ, Malluche HH (2001) Parathyroid hormone/parathyroid hormone-related peptide type 1 receptor in human bone. J Bone Min Res 16:448–456 ArticleCAS Google Scholar
Li X, Zhang Y, Kang H, Liu W,Liu P, Zhang J, Harris SE, Wu D (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883–19887 ArticlePubMedCAS Google Scholar
Noda M (2006) BMP and its antagonist. Bonekey-osteovision April 3(4):5–11 Google Scholar
Ott S (2005) Sclerostin and Wnt signaling -The pathway to bone strength. J Clin Endocrinol Metab 90:6741–6743 ArticlePubMedCAS Google Scholar
Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842–1844 PubMedCAS Google Scholar
Raisz LG (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115:3318–3325 ArticlePubMedCAS Google Scholar
Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S (2003) BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 18:1842–1843 ArticlePubMedCAS Google Scholar
Robling AG, Bellido TM, Turner CH (2006) Mechanical loading reduces osteocyte expression of sclerostin protein. J Bone Miner Res Sep 21(Suppl 1):S72 Google Scholar
Shibutani M, Uneyama C, Miyazaki K, Toyoda K, Hirose M (2000) Methacarn fixation: a novel tool for analysis of gene expressions in paraffin-embedded tissue specimens. Lab Invest 80:199–208 ArticlePubMedCAS Google Scholar
Silvestrini G, Ballanti P, Patacchioli FR, Mocetti P, Di Grezia R, Martin Wedard B, Angelucci L, Bonucci E (2000) Evaluation of apoptosis and the glucocorticoid receptor in the cartilage growth plate and metaphyseal bone cells of rats after high dose chronic treatment with corticosterone. Bone 26:33–42 ArticlePubMedCAS Google Scholar
Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever P (2005) Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J CELL SCI 119:1283–1296 ArticleCAS Google Scholar
Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA (2004) Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35:828–835 ArticlePubMedCAS Google Scholar
Tobimatsu T, Kaji H, Sowa H, Naito J, Canaff L, Hendy GN, Sugimoto T, Chihara K (2006) Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology 147:2583–2590 ArticlePubMedCAS Google Scholar
Uneyama C, Shibutani M, Masutomi N, Takagi H, Hirose M (2002) Methacarn Fixation for Genomic DNA Analysis in Microdissected, Paraffin-embedded Tissue Specimens. J Histochem Cytochem 50:1237–1245 PubMedCAS Google Scholar
van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H,Papapoulos SE, ten Dijke P, Lowik CW (2006a) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805–814 ArticleCAS Google Scholar
van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW (2006b) SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16:319–327 ArticleCAS Google Scholar
Wergedal JE, Veskovic K, Hellan M, Nyght C, Balemans W, Libanati C, Vanhoenacker FM, Tan J, Baylink DJ, Van Hul W (2003) Patients with Van Buchem Disease, an Osteosclerotic Genetic Disease, Have Elevated Bone Formation Markers, Higher Bone Density, and Greater Derived Polar Moment of Inertia than Normal. J Clin Endocrinol Metab 88:5778–5783 ArticlePubMedCAS Google Scholar
Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267–6276 ArticlePubMedCAS Google Scholar